Incidence of constipation associated with long-acting opioid therapy: A comparative study

被引:50
|
作者
Staats, PS
Markwitz, J
Schein, J
机构
[1] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Hlth Data Analyt, Princeton, NJ USA
[4] Janssen Pharmaceut Prod LP, Titusville, NJ USA
关键词
constipation; fentanyl transdermal system; morphine; controlled-release; opioid analgesics; oxycodone controlled-release;
D O I
10.1097/01.SMJ.0000109215.54052.D8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy. Methods: A retrospective cohort design study was conducted determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared. Results: A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group. Conclusion: In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 50 条
  • [41] OLANZAPINE "LONG-ACTING" IN MAINTENANCE THERAPY OF SCHIZOPHRENIA: A STUDY WITH PLASMA LEVELS
    Altamura, A. C.
    Rovera, Chiara
    Di Pace, C.
    Paletta, S.
    De Gaspari, I. F.
    MAuri, M. C.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S299 - S300
  • [42] "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels
    Mauri, Massimo C.
    Maffini, Michele
    Di Pace, Chiara
    Reggiori, Alessandra
    Paletta, Silvia
    Moliterno, Donatella
    Rovera, Chiara
    Altamura, Carlo A.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2015, 19 (02) : 99 - 105
  • [43] COMPLICATIONS OF LONG-ACTING SOMATOSTATIN ANALOG THERAPY
    JACKSON, JA
    AMERICAN JOURNAL OF MEDICINE, 1989, 86 (04): : 512 - 513
  • [44] An update on long-acting agents in HIV therapy
    Pezzati, Laura
    Canavesi, Giada
    Rusconi, Stefano
    FUTURE VIROLOGY, 2023, 18 (13) : 881 - 893
  • [45] Long-acting hydrocortisone for glucocorticoid replacement therapy
    Johannsson, Gudmundur
    Filipsson, Helena
    Bergthorsdottir, Ragnhildur
    Lennernaes, Hans
    Skrtic, Stanko
    HORMONE RESEARCH, 2007, 68 : 182 - 188
  • [46] COMPARATIVE THERAPEUTIC TRIAL OF A COMBINED PREPARATION OF LONG-ACTING THEOPHYLLINE AND AMBROXOL VS LONG-ACTING THEOPHYLLINE ALONE
    KOLAROV, G
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1990, 132 (16): : 264 - 267
  • [47] Effectiveness of Short-Acting Opioid Escalation vs Initiation of a Long-Acting Opioid in Nursing Home Residents
    Nunes, Anthony P.
    Yuan, Yiyang
    Baek, Jonggyu
    Pawasauskas, Jayne
    Hume, Anne L.
    Liu, Shao-Hsien
    Lapane, Kate L.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2024, 25 (09)
  • [48] DESIGN, SYNTHESIS, AND PHARMACOLOGICAL EVALUATION OF ULTRASHORT-ACTING TO LONG-ACTING OPIOID ANALGESICS
    FELDMAN, PL
    JAMES, MK
    BRACKEEN, MF
    BILOTTA, JM
    SCHUSTER, SV
    LAHEY, AP
    LUTZ, MW
    JOHNSON, MR
    LEIGHTON, HJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) : 2202 - 2208
  • [49] Post-operative opioid dosing relative to preoperative long-acting opioid dose
    Uhrbrand, Peter
    Papadomanolakis-Pakis, Nicholas
    Nikolajsen, Lone
    DANISH MEDICAL JOURNAL, 2022, 69 (08):
  • [50] COMPARATIVE-STUDY OF THE LONG-ACTING NEUROLEPTICS PERPHENAZIN-ENANTHATE AND FLUSPIRILENE
    TEGELER, J
    FLORU, L
    PHARMAKOPSYCHIATRIE NEURO-PSYCHOPHARMAKOLOGIE, 1979, 12 (05): : 357 - 365